CASI Pharmaceuticals (CASIF) Receivables - Other (2021 - 2024)

CASI Pharmaceuticals' (CASIF) quarterly Receivables - Other came in at $209000.0 in Q1 2024, up 248.33% on a QoQ basis from $60000.0 in Q4 2022.

CASI Pharmaceuticals (CASIF) Receivables - Other (2021 - 2024) Analysis & Trends

CASI Pharmaceuticals (CASIF) has 3 years of Receivables - Other data on file, last reported at $209000.0 in Q1 2024.

Quarterly Receivables - Other changed N/A year-over-year to $209000.0 in Q1 2024, while the trailing twelve-month figure through Mar 2024 was $209000.0 (changed N/A YoY) and the FY2024 annual result came in at -$587000.0, down 200.0% from the prior year.
Receivables - Other climbed to $209000.0 in Q1 2024, from $60000.0 in the prior quarter.
In the past five years, Receivables - Other ranged from a high of $209000.0 in Q1 2024 to a low of $37000.0 in Q1 2022.
A 3-year average of $95666.7 and a median of $60000.0 in 2022 frame the typical range for Receivables - Other.
The widest YoY moves for Receivables - Other: up 59.46% in 2022, down 59.46% in 2022.
Tracing CASIF's Receivables - Other over 3 years: stood at $148000.0 in 2021, then tumbled by 59.46% to $60000.0 in 2022, then soared by 248.33% to $209000.0 in 2024.
The last three Receivables - Other figures came in at $209000.0 (Q1 2024), $60000.0 (Q4 2022), and $60000.0 (Q3 2022), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	CASI Pharmaceuticals	2.65 Mn	-3.76 Bn	-

Download Data